Anticancer effects and the mechanism underlying 2-methoxyestradiol in human osteosarcoma in vitro and in vivo

Xiaoyan Tang1, Fenghua Tao2, Wei Xiang2

  • 1General Department, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China.

Oncology Letters
|September 1, 2020
PubMed

Insights

2-methoxyestradiol (2-ME) effectively inhibits osteosarcoma (OS) cell proliferation and induces apoptosis. This study reveals 2-ME

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Osteosarcoma (OS) is a prevalent bone cancer in children and adolescents with a poor prognosis.
  • 2-methoxyestradiol (2-ME) exhibits antitumor properties but shows limited efficacy in OS.
  • Investigating 2-ME's effects on OS cells is crucial for developing novel therapeutic strategies.

Purpose of the Study:

  • To evaluate the impact of 2-methoxyestradiol (2-ME) on the proliferation and apoptosis of human MG63 osteosarcoma (OS) cells.
  • To elucidate the underlying biological mechanisms of 2-ME's action in OS.
  • To assess the in vivo efficacy and safety of 2-ME in a preclinical model.

Main Methods:

  • Human MG63 OS cells were treated with varying concentrations of 2-ME.
  • Cell proliferation, cell cycle, and apoptosis were assessed using standard assays.
  • Expression levels of VEGF, Bcl-2, and caspase-3 were quantified via Western blotting and RT-qPCR.
  • Tumor growth inhibition and toxicity were evaluated in a nude mouse xenograft model.

Main Results:

  • 2-ME significantly inhibited OS cell proliferation in a time- and dose-dependent manner.
  • 2-ME induced G2/M phase cell cycle arrest and promoted early apoptosis.
  • 2-ME treatment led to decreased expression of VEGF and Bcl-2, and increased expression of caspase-3.
  • In vivo studies showed tumor growth suppression by 2-ME without observable liver or kidney toxicity.

Conclusions:

  • 2-methoxyestradiol (2-ME) demonstrates potent anti-proliferative and pro-apoptotic effects on osteosarcoma (OS) cells in vitro and in vivo.
  • The anticancer mechanism of 2-ME involves the modulation of VEGF, Bcl-2, and caspase-3 expression.
  • 2-ME represents a promising therapeutic agent for osteosarcoma with a favorable safety profile.

Related Concept Videos